Merck KGaA - Product Pipeline Review - 2015

  • ID: 3387843
  • Company Profile
  • 112 pages
  • Global Markets Direct
  • Merck Group
1 of 3
Merck KGaA - Product Pipeline Review - 2015

Summary

The report ‘Merck KGaA - Product Pipeline Review - 2015’, provides an overview of the Merck KGaA’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merck KGaA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merck KGaA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merck KGaA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Merck KGaA’s pipeline products

Reasons to buy

- Evaluate Merck KGaA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merck KGaA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merck KGaA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merck KGaA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck KGaA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merck KGaA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables
List of Figures
Merck KGaA Snapshot
Merck KGaA Overview
Key Information
Key Facts
Merck KGaA - Research and Development Overview
Key Therapeutic Areas
Merck KGaA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Merck KGaA - Pipeline Products Glance
Merck KGaA - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Merck KGaA - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Merck KGaA - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Merck KGaA - Drug Profiles
cetuximab
Product Description
Mechanism of Action
R&D Progress
avelumab
Product Description
Mechanism of Action
R&D Progress
choriogonadotropin alfa
Product Description
Mechanism of Action
R&D Progress
atacicept
Product Description
Mechanism of Action
R&D Progress
ATXMS-1467
Product Description
Mechanism of Action
R&D Progress
pimasertib hydrochloride
Product Description
Mechanism of Action
R&D Progress
pimasertib hydrochloride + voxtalisib
Product Description
Mechanism of Action
R&D Progress
sprifermin
Product Description
Mechanism of Action
R&D Progress
tecemotide
Product Description
Mechanism of Action
R&D Progress
tepotinib
Product Description
Mechanism of Action
R&D Progress
BeiGene-290
Product Description
Mechanism of Action
R&D Progress
BGB-283
Product Description
Mechanism of Action
R&D Progress
DI-B4
Product Description
Mechanism of Action
R&D Progress
MSB-0010360N
Product Description
Mechanism of Action
R&D Progress
MSB-0010841
Product Description
Mechanism of Action
R&D Progress
MSC-2015103B
Product Description
Mechanism of Action
R&D Progress
MSC-2363318A
Product Description
Mechanism of Action
R&D Progress
MSC-2364447
Product Description
Mechanism of Action
R&D Progress
MSC-2490484A
Product Description
Mechanism of Action
R&D Progress
ALX-0751
Product Description
Mechanism of Action
R&D Progress
AS-605240
Product Description
Mechanism of Action
R&D Progress
cilengitide
Product Description
Mechanism of Action
R&D Progress
DDD-498
Product Description
Mechanism of Action
R&D Progress
rimeporide
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Aurora B Kinase for Cancer
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cancer-1
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cancer-2
Product Description
Mechanism of Action
R&D Progress
Next-Generation Antibody-Drug Conjugates for Cancer
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit SYK for Inflammation
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit WNT Pathway for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Multiple Sclerosis
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Oncology
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize TNFR for Cancer
Product Description
Mechanism of Action
R&D Progress
Merck KGaA - Pipeline Analysis
Merck KGaA - Pipeline Products by Target
Merck KGaA - Pipeline Products by Route of Administration
Merck KGaA - Pipeline Products by Molecule Type
Merck KGaA - Pipeline Products by Mechanism of Action
Merck KGaA - Recent Pipeline Updates
Merck KGaA - Dormant Projects
Merck KGaA - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
abituzumab
anastrozole
atacicept
cilengitide
cladribine
Drug to Antagonize Oxytocin Receptor for Pre-term Labor
EMD-1204831
emfilermin
EML-4156
matuzumab
MSB-0010445
MSB-0010841
onercept
Osteopontin
pimasertib hydrochloride
plovamer acetate
sarizotan hydrochloride
tecemotide
tucotuzumab celmoleukin
Merck KGaA - Company Statement
Merck KGaA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Merck KGaA, Key Information
Merck KGaA, Key Facts
Merck KGaA - Pipeline by Indication, 2015
Merck KGaA - Pipeline by Stage of Development, 2015
Merck KGaA - Monotherapy Products in Pipeline, 2015
Merck KGaA - Combination Treatment Modalities in Pipeline, 2015
Merck KGaA - Partnered Products in Pipeline, 2015
Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2015
Merck KGaA - Out-Licensed Products in Pipeline, 2015
Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2015
Merck KGaA - Filing rejected/Withdrawn, 2015
Merck KGaA - Phase III, 2015
Merck KGaA - Phase II, 2015
Merck KGaA - Phase I, 2015
Merck KGaA - Preclinical, 2015
Merck KGaA - Discovery, 2015
Merck KGaA - Pipeline by Target, 2015
Merck KGaA - Pipeline by Route of Administration, 2015
Merck KGaA - Pipeline by Molecule Type, 2015
Merck KGaA - Pipeline Products by Mechanism of Action, 2015
Merck KGaA - Recent Pipeline Updates, 2015
Merck KGaA - Dormant Developmental Projects,2015
Merck KGaA - Discontinued Pipeline Products, 2015
Merck KGaA, Subsidiaries

List of Figures
Merck KGaA - Pipeline by Top 10 Indication, 2015
Merck KGaA - Pipeline by Stage of Development, 2015
Merck KgaA - Monotherapy Products in Pipeline, 2015
Merck KGaA - Combination Treatment Modalities in Pipeline, 2015
Merck KGaA - Partnered Products in Pipeline, 2015
Merck KGaA - Out-Licensed Products in Pipeline, 2015
Merck KGaA - Pipeline by Top 10 Target, 2015
Merck KGaA - Pipeline by Top 10 Route of Administration, 2015
Merck KGaA - Pipeline by Top 10 Molecule Type, 2015
Merck KGaA - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll